India’s pharmaceutical exports to the United Kingdom are projected to grow by more than 8% year-on-year to approximately USD 981 million in FY2026–27, supported by the India–UK Free Trade Agreement (FTA), which is expected to improve market access, reduce trade barriers, and strengthen bilateral healthcare cooperation.
The FTA is anticipated to create new opportunities for Indian pharmaceutical manufacturers by streamlining regulatory procedures, enhancing transparency, and facilitating smoother trade in medicines and healthcare products. Industry experts believe the agreement will further reinforce India’s position as a reliable supplier of affordable, high-quality generic medicines to the UK market.
The United Kingdom is an important destination for Indian pharmaceutical exports, with demand driven by generic drugs, active pharmaceutical ingredients (APIs), vaccines, and other healthcare products. The FTA is expected to improve the competitiveness of Indian exporters by lowering compliance costs, simplifying customs processes, and encouraging greater collaboration between pharmaceutical companies in both countries.
Exporters are also expected to benefit from stronger supply chain integration, faster product approvals, and increased investment opportunities. The agreement is likely to encourage joint research, innovation, and technology partnerships, enabling Indian companies to expand their presence in the UK’s healthcare ecosystem while supporting the country’s pharmaceutical supply security.
Industry bodies have welcomed the expected gains from the FTA, noting that the agreement could help diversify export markets amid evolving global trade dynamics. The projected growth reflects continued international confidence in India’s pharmaceutical manufacturing capabilities, backed by a robust regulatory framework, cost-efficient production, and a well-established export network.
Beyond boosting exports, the FTA is expected to strengthen long-term economic ties between India and the UK, opening new avenues for trade in life sciences, biotechnology, and medical technologies. As the agreement comes into effect, Indian pharmaceutical companies are expected to leverage the improved trade environment to expand product portfolios, deepen customer relationships, and increase their market share in one of Europe’s key healthcare markets.
